cAC10-PNU

cAC10-PNU (also referred to as cAC10-Gly5-PNU or cAC10-PNU-EDA-Gly5) is an investigational, site-specifically conjugated antibody-drug conjugate (ADC) consisting of the chimeric anti-CD30 monoclonal antibody cAC10 conjugated to PNU-159682, a highly potent anthracycline-derived cytotoxic payload. The conjugation is achieved using sortase-mediated antibody conjugation (SMAC) technology, which yields a homogeneous ADC with a noncleavable Gly5 peptide linker. cAC10-PNU targets CD30 (TNFRSF8), a cell-surface receptor overexpressed in certain hematologic malignancies such as Hodgkin lymphoma and anaplastic large cell lymphoma. Upon binding and internalization, the payload PNU-159682 acts as a potent DNA-damaging agent, inducing immunogenic cell death and stimulating anti-tumor immunity.

Other names

brentuximab-PNU-EDA-Gly5brentuximab-PNU-EDA-Gly-5brentuximab-PNU-EDA-Gly 5